Results 171 to 180 of about 251,884 (333)

The potential for biased signalling in the P2Y receptor family of GPCRs

open access: yesBritish Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk   +2 more
wiley   +1 more source

Glycolysis and pyrimidine biosynthesis are required for replication of adherent–invasive Escherichia coli in macrophages

open access: green, 2016
A. Thompson   +7 more
openalex   +2 more sources

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

SLPI/FBW7/c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity

open access: yesCancer Science, EarlyView.
SLPI reduces the sensitivity of PDAC to gemcitabine by competing with FBW7 for binding to c‐Myc, thereby disrupting FBW7‐dependent ubiquitination and proteasomal degradation of c‐Myc, leading to increased c‐Myc stability and expression. SLPI knockdown could significantly increase gemcitabine sensitivity to gemcitabine‐induced direct cytotoxicity and NK
Haofei Chen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy